Last updated: 2026-02-18 19:43:06 ET
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.
Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to rejec...
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal inf...
In February 2026, Moderna reported full-year 2025 revenue of US$1.94 billion and a net loss of US$2.82 billion, while the FDA’s vaccines ...
Moderna’s stock was surging after the FDA said it would review the biotech’s flu-vaccine candidate, a week after it had refused to do so.
The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza seas...
Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults after all
Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults after all.
